Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder
Identifieur interne : 000221 ( Main/Exploration ); précédent : 000220; suivant : 000222Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder
Auteurs : Ronald B. Postuma [Canada] ; Jean-François Gagnon [Canada] ; Mélanie Vendette [Canada] ; Catherine Desjardins [Canada] ; Jacques Y. Montplaisir [Canada]Source :
- Annals of Neurology [ 0364-5134 ] ; 2011-05.
Abstract
Objective:: For development of neuroprotective therapy, neurodegenerative disease must be identified as early as possible. However, current means of identifying “preclinical” neurodegeneration are limited. Patients with idiopathic rapid eye movement (REM) sleep behavior disorder (RBD) are at >50% risk of synuclein‐mediated neurodegenerative disease—this provides a unique opportunity to directly observe preclinical synucleinopathy and to test potential markers of preclinical disease. Methods:: Patients with RBD without neurodegenerative disease were enrolled in a prospective cohort starting in 2004. Olfaction and color vision were tested at baseline, then annually for 5 years. Test results were compared between patients who developed neurodegenerative disease and those who remained disease‐free. Results:: Out of 64 patients, 62 (97%) participated in annual follow‐up. During follow‐up, 21 developed disease, and 41 remained disease‐free. Out of 21, 16 developed a combination of parkinsonism and dementia, 4 developed isolated parkinsonism (all with tremor), and 1 developed isolated dementia. Compared to those remaining disease‐free, patients destined to develop disease had worse baseline olfaction (University of Pennsylvania Smell Identification Test [UPSIT] = 58.3 ± 27.0% age/sex‐adjusted normal vs 80.2 ± 26.3%; p = 0.003) and color vision (Farnsworth‐Munsell 100‐Hue color test [FM‐100] errors 153.0 ± 82.2% normal vs 120.2 ± 26.5%; p = 0.022). Kaplan‐Meier 5‐year‐disease‐free survival in those with normal olfaction was 86.0%, vs 35.4% with impaired olfaction (p = 0.029). Disease‐free survival with normal color vision was 70.3%, vs 26.0% with impaired vision (p = 0.009). Both olfaction and color vision were reduced as much as 5 years before disease diagnosis, with only slight decline in preclinical stages. Interpretation:: Olfaction and color vision identify early‐stage synuclein‐mediated neurodegenerative diseases. In most cases, abnormalities are measurable at least 5 years before disease onset, and progress slowly in the preclinical stages. Ann Neurol 2011;
Url:
DOI: 10.1002/ana.22282
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder</title>
<author><name sortKey="Postuma, Ronald B" sort="Postuma, Ronald B" uniqKey="Postuma R" first="Ronald B." last="Postuma">Ronald B. Postuma</name>
</author>
<author><name sortKey="Gagnon, Jean Rancois" sort="Gagnon, Jean Rancois" uniqKey="Gagnon J" first="Jean-François" last="Gagnon">Jean-François Gagnon</name>
</author>
<author><name sortKey="Vendette, Melanie" sort="Vendette, Melanie" uniqKey="Vendette M" first="Mélanie" last="Vendette">Mélanie Vendette</name>
</author>
<author><name sortKey="Desjardins, Catherine" sort="Desjardins, Catherine" uniqKey="Desjardins C" first="Catherine" last="Desjardins">Catherine Desjardins</name>
</author>
<author><name sortKey="Montplaisir, Jacques Y" sort="Montplaisir, Jacques Y" uniqKey="Montplaisir J" first="Jacques Y." last="Montplaisir">Jacques Y. Montplaisir</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:B4900BCBB2BBCB01C57569296C35331FD6F6E415</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1002/ana.22282</idno>
<idno type="url">https://api.istex.fr/document/B4900BCBB2BBCB01C57569296C35331FD6F6E415/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">000271</idno>
<idno type="wicri:Area/Main/Curation">000225</idno>
<idno type="wicri:Area/Main/Exploration">000221</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder</title>
<author><name sortKey="Postuma, Ronald B" sort="Postuma, Ronald B" uniqKey="Postuma R" first="Ronald B." last="Postuma">Ronald B. Postuma</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Neurology, McGill University, Montreal General Hospital, Montreal, Quebec</wicri:regionArea>
<orgName type="university">Université McGill</orgName>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Centre d'étude du sommeil et des rythmes biologiques, Hôpital du Sacré‐Coeur, Montréal, Québec</wicri:regionArea>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gagnon, Jean Rancois" sort="Gagnon, Jean Rancois" uniqKey="Gagnon J" first="Jean-François" last="Gagnon">Jean-François Gagnon</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Centre d'étude du sommeil et des rythmes biologiques, Hôpital du Sacré‐Coeur, Montréal, Québec</wicri:regionArea>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Psychiatry, Université de Montréal, Quebec</wicri:regionArea>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Vendette, Melanie" sort="Vendette, Melanie" uniqKey="Vendette M" first="Mélanie" last="Vendette">Mélanie Vendette</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Centre d'étude du sommeil et des rythmes biologiques, Hôpital du Sacré‐Coeur, Montréal, Québec</wicri:regionArea>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Desjardins, Catherine" sort="Desjardins, Catherine" uniqKey="Desjardins C" first="Catherine" last="Desjardins">Catherine Desjardins</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Centre d'étude du sommeil et des rythmes biologiques, Hôpital du Sacré‐Coeur, Montréal, Québec</wicri:regionArea>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Psychiatry, Université de Montréal, Quebec</wicri:regionArea>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Montplaisir, Jacques Y" sort="Montplaisir, Jacques Y" uniqKey="Montplaisir J" first="Jacques Y." last="Montplaisir">Jacques Y. Montplaisir</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Centre d'étude du sommeil et des rythmes biologiques, Hôpital du Sacré‐Coeur, Montréal, Québec</wicri:regionArea>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Psychiatry, Université de Montréal, Quebec</wicri:regionArea>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of Neurology</title>
<title level="j" type="abbrev">Ann Neurol.</title>
<idno type="ISSN">0364-5134</idno>
<idno type="eISSN">1531-8249</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2011-05">2011-05</date>
<biblScope unit="volume">69</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="811">811</biblScope>
<biblScope unit="page" to="818">818</biblScope>
</imprint>
<idno type="ISSN">0364-5134</idno>
</series>
<idno type="istex">B4900BCBB2BBCB01C57569296C35331FD6F6E415</idno>
<idno type="DOI">10.1002/ana.22282</idno>
<idno type="ArticleID">ANA22282</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0364-5134</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective:: For development of neuroprotective therapy, neurodegenerative disease must be identified as early as possible. However, current means of identifying “preclinical” neurodegeneration are limited. Patients with idiopathic rapid eye movement (REM) sleep behavior disorder (RBD) are at >50% risk of synuclein‐mediated neurodegenerative disease—this provides a unique opportunity to directly observe preclinical synucleinopathy and to test potential markers of preclinical disease. Methods:: Patients with RBD without neurodegenerative disease were enrolled in a prospective cohort starting in 2004. Olfaction and color vision were tested at baseline, then annually for 5 years. Test results were compared between patients who developed neurodegenerative disease and those who remained disease‐free. Results:: Out of 64 patients, 62 (97%) participated in annual follow‐up. During follow‐up, 21 developed disease, and 41 remained disease‐free. Out of 21, 16 developed a combination of parkinsonism and dementia, 4 developed isolated parkinsonism (all with tremor), and 1 developed isolated dementia. Compared to those remaining disease‐free, patients destined to develop disease had worse baseline olfaction (University of Pennsylvania Smell Identification Test [UPSIT] = 58.3 ± 27.0% age/sex‐adjusted normal vs 80.2 ± 26.3%; p = 0.003) and color vision (Farnsworth‐Munsell 100‐Hue color test [FM‐100] errors 153.0 ± 82.2% normal vs 120.2 ± 26.5%; p = 0.022). Kaplan‐Meier 5‐year‐disease‐free survival in those with normal olfaction was 86.0%, vs 35.4% with impaired olfaction (p = 0.029). Disease‐free survival with normal color vision was 70.3%, vs 26.0% with impaired vision (p = 0.009). Both olfaction and color vision were reduced as much as 5 years before disease diagnosis, with only slight decline in preclinical stages. Interpretation:: Olfaction and color vision identify early‐stage synuclein‐mediated neurodegenerative diseases. In most cases, abnormalities are measurable at least 5 years before disease onset, and progress slowly in the preclinical stages. Ann Neurol 2011;</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
<region><li>Québec</li>
</region>
<settlement><li>Montréal</li>
</settlement>
<orgName><li>Université McGill</li>
</orgName>
</list>
<tree><country name="Canada"><region name="Québec"><name sortKey="Postuma, Ronald B" sort="Postuma, Ronald B" uniqKey="Postuma R" first="Ronald B." last="Postuma">Ronald B. Postuma</name>
</region>
<name sortKey="Desjardins, Catherine" sort="Desjardins, Catherine" uniqKey="Desjardins C" first="Catherine" last="Desjardins">Catherine Desjardins</name>
<name sortKey="Desjardins, Catherine" sort="Desjardins, Catherine" uniqKey="Desjardins C" first="Catherine" last="Desjardins">Catherine Desjardins</name>
<name sortKey="Gagnon, Jean Rancois" sort="Gagnon, Jean Rancois" uniqKey="Gagnon J" first="Jean-François" last="Gagnon">Jean-François Gagnon</name>
<name sortKey="Gagnon, Jean Rancois" sort="Gagnon, Jean Rancois" uniqKey="Gagnon J" first="Jean-François" last="Gagnon">Jean-François Gagnon</name>
<name sortKey="Montplaisir, Jacques Y" sort="Montplaisir, Jacques Y" uniqKey="Montplaisir J" first="Jacques Y." last="Montplaisir">Jacques Y. Montplaisir</name>
<name sortKey="Montplaisir, Jacques Y" sort="Montplaisir, Jacques Y" uniqKey="Montplaisir J" first="Jacques Y." last="Montplaisir">Jacques Y. Montplaisir</name>
<name sortKey="Postuma, Ronald B" sort="Postuma, Ronald B" uniqKey="Postuma R" first="Ronald B." last="Postuma">Ronald B. Postuma</name>
<name sortKey="Vendette, Melanie" sort="Vendette, Melanie" uniqKey="Vendette M" first="Mélanie" last="Vendette">Mélanie Vendette</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000221 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000221 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:B4900BCBB2BBCB01C57569296C35331FD6F6E415 |texte= Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder }}
This area was generated with Dilib version V0.6.23. |